This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Is Most-Watched Stock Altria Group, Inc. (MO) Worth Betting on Now?
by Zacks Equity Research
Altria (MO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Altria (MO) Q2 Earnings Surpass Estimates, Revenues Drop Y/Y
by Zacks Equity Research
Altria Group's (MO) second-quarter 2022 results reflect increased earnings. Pricing remains an upside, though shipment volumes appear soft.
Altria (MO) Q2 Earnings Top Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 0.80% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Altria (MO)
by Zacks Equity Research
Altria (MO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Hershey (HSY) Queues Up for Q2 Earnings: What to Expect?
by Zacks Equity Research
Hershey's (HSY) second-quarter 2022 results are likely to reflect gains from pricing and acquisitions, whereas elevated costs are likely to have been a concern.
Altria Group (MO) Readies for Q2 Earnings: What to Expect?
by Zacks Equity Research
Altria Group's (MO) second-quarter 2022 results are likely to reflect gains from pricing and strength in oral tobacco products, whereas elevated costs are likely to have been a concern.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $43.09, moving +0.75% from the previous trading session.
Altria (MO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $42.77 in the latest trading session, marking a +1.06% move from the prior day.
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $41.99, marking a +0.86% move from the previous day.
Is Invesco S&P 500 Equal Weight Consumer Staples ETF (RHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RHS
Things to Note as Philip Morris (PM) Lines Up for Q2 Earnings
by Zacks Equity Research
Philip Morris' (PM) second-quarter 2022 results are likely to reflect cost concerns and certain hurdles related to the pandemic, whereas strong pricing is likely to have remained an upside.
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $41.95, moving +1.04% from the previous trading session.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $41.72 in the latest trading session, marking a -1.25% move from the prior day.
Should You Invest in the Invesco S&P 500 Equal Weight Consumer Staples ETF (RHS)?
by Zacks Equity Research
Sector ETF report for RHS
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $43.19, moving -0.48% from the previous trading session.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Altria (MO) Stock Moves -0.63%: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $45.38, marking a -0.63% move from the previous day.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $45.67, marking a -1.34% move from the previous day.
Altria (MO) Stock Moves -1.68%: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $48.66, marking a -1.68% move from the previous day.
Altria (MO) Stock Moves -0.61%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $53.82 in the latest trading session, marking a -0.61% move from the prior day.
Altria (MO) Benefits From Solid Pricing, High Costs a Worry
by Zacks Equity Research
Altria (MO) has been benefiting from its solid pricing power and efforts toward expanding in the oral tobacco products space, while escalation in certain costs is a concern.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY